according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fluralaner / Moxidectin / Pyrantel Pamoate Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 7950971-00012
 Date of first issue: 17.03.2021

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Trade name : Fluralaner / Moxidectin / Pyrantel Pamoate Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub- : Veterinary product

stance/Mixture

Recommended restrictions

on use

Not applicable

1.3 Details of the supplier of the safety data sheet

Company : MSD

Kilsheelan

Clonmel Tipperary, IE

Telephone : 353-51-601000

E-mail address of person

responsible for the SDS

: EHSDATASTEWARD@msd.com

1.4 Emergency telephone number

1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)

Reproductive toxicity, Category 2 H361d: Suspected of damaging the unborn child.

Short-term (acute) aquatic hazard, Cate- H400: Very toxic to aquatic life.

gory 1

Long-term (chronic) aquatic hazard, Cat-

egory 1

H410: Very toxic to aquatic life with long lasting

effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms



*

Signal word : Warning

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fluralaner / Moxidectin / Pyrantel Pamoate Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5.1 28.09.2024 7950971-00012 Date of first issue: 17.03.2021

Hazard statements : H361d Suspected of damaging the unborn child.

H410 Very toxic to aquatic life with long lasting effects.

Precautionary statements : Prevention:

P201 Obtain special instructions before use.

P273 Avoid release to the environment.

P280 Wear protective gloves/ protective clothing/ eye

protection/ face protection.

Response:

P308 + P313 IF exposed or concerned: Get medical advice/

attention.

P391 Collect spillage.

Storage:

P405 Store locked up.

Hazardous components which must be listed on the label:

Fluralaner

Additional Labelling

The following percentage of the mixture consists of ingredient(s) with unknown hazards to the aquatic environment: 18 %

2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.

May form explosive dust-air mixture during processing, handling or other means.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
4,4'-methylenebis[3-hydroxy-2-	22204-24-6		>= 10 - < 20

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fluralaner / Moxidectin / Pyrantel Pamoate Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 7950971-00012
 Date of first issue: 17.03.2021

naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1)	244-837-1		
Fluralaner	864731-61-3	Repr. 2; H361d Aquatic Chronic 1; H410	>= 10 - < 20
		M-Factor (Chronic aquatic toxicity): 1,000	
Sodium n-dodecyl sulfate	151-21-3 205-788-1	Acute Tox. 4; H302 Skin Irrit. 2; H315 Eye Dam. 1; H318 Aquatic Chronic 3; H412	>= 1 - < 2.5
		specific concentration limit Eye Irrit. 2; H319 10 - < 20 % Eye Dam. 1; H318 >= 20 %	
		Acute toxicity estimate Acute oral toxicity:	
2,6-Di-tert-butyl-p-cresol	128-37-0 204-881-4	1,200 mg/kg Aquatic Acute 1; H400 Aquatic Chronic 1; H410	>= 0.1 - < 0.25
		M-Factor (Acute aquatic toxicity): 1 M-Factor (Chronic aquatic toxicity): 1	
Moxidectin	113507-06-5	Acute Tox. 3; H301 Acute Tox. 4; H332 Eye Irrit. 2; H319 Repr. 2; H361d STOT RE 1; H372 (Central nervous system) Aquatic Acute 1; H400 Aquatic Chronic 1; H410	>= 0.025 - < 0.1

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fluralaner / Moxidectin / Pyrantel Pamoate Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024
5.1 28.09.2024 7950971-00012 Date of first issue: 17.03.2021

| M-Factor (Acute aquatic toxicity): 10,000 M-Factor (Chronic aquatic toxicity): 10,000

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical ad-

vice immediately.

When symptoms persist or in all cases of doubt seek medical

advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection,

and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air.

Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with plenty of water.

Remove contaminated clothing and shoes.

Get medical attention.

Wash clothing before reuse.

Thoroughly clean shoes before reuse.

In case of eye contact : If in eyes, rinse well with water.

Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting.

Get medical attention.

Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks : Suspected of damaging the unborn child.

Dust contact with the eyes can lead to mechanical irritation.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fluralaner / Moxidectin / Pyrantel Pamoate Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5.1 28.09.2024 7950971-00012 Date of first issue: 17.03.2021

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media : Water spray

Alcohol-resistant foam Carbon dioxide (CO2)

Dry chemical

Unsuitable extinguishing

media

None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-

fighting

: Exposure to combustion products may be a hazard to health.

Hazardous combustion prod: :

ucts

Carbon oxides

Chlorine compounds Fluorine compounds Nitrogen oxides (NOx)

Sulphur oxides Metal oxides Silicon oxides

5.3 Advice for firefighters

Special protective equipment:

for firefighters

In the event of fire, wear self-contained breathing apparatus.

Use personal protective equipment.

Specific extinguishing meth-

ods

Use extinguishing measures that are appropriate to local cir-

cumstances and the surrounding environment. Use water spray to cool unopened containers.

Remove undamaged containers from fire area if it is safe to do

SO.

Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.

Follow safe handling advice (see section 7) and personal pro-

tective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.

Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

cannot be contained.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fluralaner / Moxidectin / Pyrantel Pamoate Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5.1 28.09.2024 7950971-00012 Date of first issue: 17.03.2021

6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable con-

tainer for disposal.

Avoid dispersal of dust in the air (i.e., clearing dust surfaces

with compressed air).

Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to deter-

mine which regulations are applicable.

Sections 13 and 15 of this SDS provide information regarding

certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : Static electricity may accumulate and ignite suspended dust

causing an explosion.

Provide adequate precautions, such as electrical grounding

and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not get on skin or clothing.

Do not breathe dust.

Do not swallow.

Avoid contact with eyes.

Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure as-

sessment

Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.

Take precautionary measures against static discharges. Take care to prevent spills, waste and minimize release to the

environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye

flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contami-

nated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the

use of administrative controls.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fluralaner / Moxidectin / Pyrantel Pamoate Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5.1 28.09.2024 7950971-00012 Date of first issue: 17.03.2021

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers

: Keep in properly labelled containers. Store locked up. Store in

accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:

Strong oxidizing agents

7.3 Specific end use(s)

Specific use(s) : No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

Occupational Exposure Limits

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Cellulose	9004-34-6	OELV - 8 hrs (TWA)	10 mg/m3	IE OEL
4,4'- methylenebis[3- hydroxy-2- naphthoic] acid, compound with (E)-1,4,5,6- tetrahydro-1- methyl-2-[2-(2- thienyl)vinyl]pyrimi dine (1:1)	22204-24-6	TWA	250 μg/m3 (OEB 2)	Internal
Fluralaner	864731-61- 3	TWA	100 μg/m3 (OEB 2)	Internal
	Further information: Skin			
		Wipe limit	1000 μg/100 cm ²	Internal
2,6-Di-tert-butyl-p- cresol	128-37-0	OELV - 8 hrs (TWA)	2 mg/m3	IE OEL
Moxidectin	113507-06- 5	TWA	10 μg/m3 (OEB 3)	Internal
		Wipe limit	100 μg/100 cm ²	Internal

Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

	` '		` '	
Substance name	End Use	Exposure routes	Potential health ef-	Value
			fects	
Sodium n-dodecyl sulfate	Workers	Inhalation	Long-term systemic effects	285 mg/m3
	Workers	Skin contact	Long-term systemic effects	4060 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic	85 mg/m3

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fluralaner / Moxidectin / Pyrantel Pamoate Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 7950971-00012
 Date of first issue: 17.03.2021

			effects	
	Consumers	Skin contact	Long-term systemic effects	2440 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	24 mg/kg bw/day
2,6-Di-tert-butyl-p- cresol	Workers	Inhalation	Long-term systemic effects	3.5 mg/m3
	Workers	Dermal	Long-term systemic effects	0.5 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	0.86 mg/m3
	Consumers	Dermal	Long-term systemic effects	0.25 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	0.25 mg/kg bw/day

Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Fluralaner	Water	7 ng/l
Sodium n-dodecyl sulfate	Fresh water	0.176 mg/l
	Marine water	0.018 mg/l
	Sewage treatment plant	1.35 mg/l
	Fresh water sediment	6.97 mg/kg dry weight (d.w.)
	Marine sediment	0.697 mg/kg dry weight (d.w.)
	Soil	1.29 mg/kg dry weight (d.w.)
Moxidectin	Water	0.3 ng/l
2,6-Di-tert-butyl-p-cresol	Fresh water	0.199 µg/l
	Intermittent use/release	0.02 μg/l
	Marine water	0.02 μg/l
	Sewage treatment plant	0.17 mg/l
	Fresh water sediment	0.0996 mg/kg dry weight (d.w.)
	Marine sediment	0.00996 mg/kg dry weight (d.w.)
	Soil	0.04769 mg/kg dry weight (d.w.)
	Oral (Secondary Poisoning)	8.33 mg/kg food

8.2 Exposure controls

Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

Personal protective equipment

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fluralaner / Moxidectin / Pyrantel Pamoate Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 7950971-00012
 Date of first issue: 17.03.2021

Eye/face protection : Wear safety glasses with side shields or goggles.

If the work environment or activity involves dusty conditions,

mists or aerosols, wear the appropriate goggles.

Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or

aerosols.

Hand protection

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

Skin and body protection : Work uniform or laboratory coat.

Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis-

posable suits) to avoid exposed skin surfaces.

Use appropriate degowning techniques to remove potentially

contaminated clothing.

Respiratory protection : If adequate local exhaust ventilation is not available or expo-

sure assessment demonstrates exposures outside the rec-

ommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 143

Filter type : Particulates type (P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Physical state : solid

Colour : light pink, to, light brown

Odour : aromatic

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling

range

No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, han-

dling or other means.

Flammability (liquids) : Not applicable

Upper explosion limit / Upper

flammability limit

No data available

Lower explosion limit / Lower

flammability limit

No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fluralaner / Moxidectin / Pyrantel Pamoate Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5.1 28.09.2024 7950971-00012 Date of first issue: 17.03.2021

Flash point : Not applicable

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity

Viscosity, kinematic : Not applicable

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-

octanol/water

Not applicable

Vapour pressure : Not applicable

Relative density : No data available

Density : No data available

Relative vapour density : Not applicable

Particle characteristics

Particle size : No data available

9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : Not applicable

Molecular weight : No data available

SECTION 10: Stability and reactivity

10.1 Reactivity

Not classified as a reactivity hazard.

10.2 Chemical stability

Stable under normal conditions.

10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, han-

dling or other means.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fluralaner / Moxidectin / Pyrantel Pamoate Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 7950971-00012
 Date of first issue: 17.03.2021

Can react with strong oxidizing agents.

10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.

Avoid dust formation.

10.5 Incompatible materials

Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products

No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Inhalation

exposure Skin contact Ingestion

Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 2,000 mg/kg

Method: Calculation method

Components:

4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Acute oral toxicity : LD50 (Rat): > 24,000 mg/kg

LD50 (Mouse): > 24,000 mg/kg

LD50 (Dog): 2,000 mg/kg

Fluralaner:

Acute oral toxicity : LD50 (Rat): > 2,000 mg/kg

Remarks: No mortality observed at this dose. No significant adverse effects were reported

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

Remarks: No significant adverse effects were reported

Sodium n-dodecyl sulfate:

Acute oral toxicity : LD50 (Rat): 1,200 mg/kg

Method: OECD Test Guideline 401

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fluralaner / Moxidectin / Pyrantel Pamoate Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 7950971-00012
 Date of first issue: 17.03.2021

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 402

Remarks: Based on data from similar materials

2,6-Di-tert-butyl-p-cresol:

Acute oral toxicity : LD50 (Rat): > 6,000 mg/kg

Method: OECD Test Guideline 401

Acute dermal toxicity : LD50 (Rat): > 2,000 mg/kg

Method: OECD Test Guideline 402

Assessment: The substance or mixture has no acute dermal

toxicity

Moxidectin:

Acute oral toxicity : LD50 (Rat): 106 mg/kg

LD50 (Mouse): 42 - 84 mg/kg

Acute inhalation toxicity : LC50 (Rat): 3.28 mg/l

Exposure time: 5 h

Test atmosphere: dust/mist

LC50 (Rat): 2.87 - 4.06 mg/l Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Remarks: No significant adverse effects were reported

Acute toxicity (other routes of:

administration)

LD50 (Rat): 394 mg/kg

Application Route: Intraperitoneal

LD50 (Mouse): 84 mg/kg

Application Route: Intraperitoneal

LD50 (Rat): > 640 mg/kg

Application Route: Subcutaneous

LD50 (Mouse): 263 mg/kg

Application Route: Subcutaneous

Skin corrosion/irritation

Not classified based on available information.

Components:

Fluralaner:

Species : Rabbit

Result : No skin irritation

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fluralaner / Moxidectin / Pyrantel Pamoate Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 7950971-00012
 Date of first issue: 17.03.2021

Sodium n-dodecyl sulfate:

Species : Rabbit Result : Skin irritation

2,6-Di-tert-butyl-p-cresol:

Species : Rabbit

Method : OECD Test Guideline 404

Result : No skin irritation

Remarks : Based on data from similar materials

Moxidectin:

Species : Rabbit

Result : Mild skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:

Fluralaner:

Species : Rabbit

Result : Mild eye irritation

Sodium n-dodecyl sulfate:

Species : Rabbit

Method : OECD Test Guideline 405
Result : Irreversible effects on the eye

2,6-Di-tert-butyl-p-cresol:

Species : Rabbit

Method : OECD Test Guideline 405

Result : No eye irritation

Remarks : Based on data from similar materials

Moxidectin:

Species : Rabbit

Result : Moderate eye irritation

Respiratory or skin sensitisation

Skin sensitisation

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fluralaner / Moxidectin / Pyrantel Pamoate Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5.1 28.09.2024 7950971-00012 Date of first issue: 17.03.2021

Components:

Fluralaner:

Test Type : Maximisation Test

Exposure routes : Dermal Species : Guinea pig

Result : Not a skin sensitizer.

Sodium n-dodecyl sulfate:

Test Type : Maximisation Test
Exposure routes : Skin contact
Species : Guinea pig
Result : negative

Remarks : Based on data from similar materials

2,6-Di-tert-butyl-p-cresol:

Test Type : Human repeat insult patch test (HRIPT)

Exposure routes : Skin contact Species : Humans Result : negative

Moxidectin:

Test Type : Buehler Test Exposure routes : Dermal Species : Guinea pig

Result : Not a skin sensitizer.

Germ cell mutagenicity

Not classified based on available information.

Components:

4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Fluralaner:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: Mouse Lymphoma

Result: negative

Test Type: Chromosomal aberration

Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fluralaner / Moxidectin / Pyrantel Pamoate Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5.1 28.09.2024 7950971-00012 Date of first issue: 17.03.2021

Species: Mouse

Cell type: Bone marrow Application Route: Oral Result: negative

Sodium n-dodecyl sulfate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Method: OECD Test Guideline 471

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Genotoxicity in vivo : Test Type: Rodent dominant lethal test (germ cell) (in vivo)

Species: Mouse

Application Route: Ingestion

Result: negative

2,6-Di-tert-butyl-p-cresol:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow

cytogenetic test, chromosomal analysis)

Species: Rat

Application Route: Ingestion

Result: negative

Moxidectin:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)

Result: negative

Test Type: In vitro mammalian cell gene mutation test

Test system: Chinese hamster ovary cells

Result: negative

Test Type: in vitro assay Test system: Escherichia coli

Result: negative

Genotoxicity in vivo : Test Type: Chromosomal aberration

Species: Rat

Cell type: Bone marrow

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fluralaner / Moxidectin / Pyrantel Pamoate Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5.1 28.09.2024 7950971-00012 Date of first issue: 17.03.2021

Result: negative

Test Type: Unscheduled DNA synthesis (UDS) test with

mammalian liver cells in vivo

Species: Rat Cell type: Liver cells Result: negative

Carcinogenicity

Not classified based on available information.

Components:

Fluralaner:

Carcinogenicity - Assess- : No data available

ment

Sodium n-dodecyl sulfate:

Species : Rat
Application Route : Ingestion
Exposure time : 2 Years

Method : OECD Test Guideline 453

Result : negative

Remarks : Based on data from similar materials

2,6-Di-tert-butyl-p-cresol:

Species : Rat
Application Route : Ingestion
Exposure time : 22 Months
Result : negative

Moxidectin:

Species : Mouse Application Route : Oral Exposure time : 2 Years

NOAEL : 4.5 mg/kg body weight

Result : negative

Species : Rat
Application Route : Oral
Exposure time : 2 Years

NOAEL : 4.5 mg/kg body weight

Result : negative

Species : Dog Application Route : Oral Exposure time : 1 Years

NOAEL : 0.5 mg/kg body weight

Result : negative

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fluralaner / Moxidectin / Pyrantel Pamoate Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5.1 28.09.2024 7950971-00012 Date of first issue: 17.03.2021

Reproductive toxicity

Suspected of damaging the unborn child.

Components:

4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 3,000 mg/kg body weight Result: No effects on fertility and early embryonic develop-

ment were detected.

Test Type: Embryo-foetal development

Species: Rabbit Application Route: Oral

Developmental Toxicity: NOAEL: 1,000 mg/kg body weight Result: No effects on fertility and early embryonic develop-

ment were detected.

Fluralaner:

Effects on fertility : Test Type: Two-generation study

Species: Rat

Application Route: Oral

General Toxicity - Parent: NOAEL: 50 mg/kg body weight General Toxicity F1: LOAEL: 100 mg/kg body weight Result: No effects on fertility, Postimplantation loss., Adverse

neonatal effects.

Test Type: One-generation reproduction toxicity study

Species: Dog

Application Route: Oral

Fertility: NOAEL: 75 mg/kg body weight

Result: No effects on fertility and early embryonic develop-

ment were detected.

Remarks: No significant adverse effects were reported

Effects on foetal develop-

ment

Test Type: Development

Species: Rat

Application Route: Oral

Developmental Toxicity: NOAEL: 100 mg/kg body weight Result: Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, No

teratogenic effects

Test Type: Development

Species: Rabbit Application Route: Oral

Developmental Toxicity: NOAEL: 10 mg/kg body weight

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fluralaner / Moxidectin / Pyrantel Pamoate Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 7950971-00012
 Date of first issue: 17.03.2021

Result: Skeletal malformations, Visceral malformations

Remarks: Maternal toxicity observed.

Test Type: Development

Species: Rabbit

Application Route: Dermal

Developmental Toxicity: NOAEL: 100 mg/kg body weight

Result: Skeletal malformations

Reproductive toxicity - As-

sessment

Suspected of damaging the unborn child.

Sodium n-dodecyl sulfate:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion Method: OECD Test Guideline 416

Result: negative

Remarks: Based on data from similar materials

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Ingestion

Result: negative

Remarks: Based on data from similar materials

2,6-Di-tert-butyl-p-cresol:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Ingestion

Result: negative

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Ingestion

Result: negative

Moxidectin:

Effects on fertility : Test Type: Two-generation reproduction toxicity study

Species: Rat

Application Route: Oral

General Toxicity F1: LOAEL: 0.8 mg/kg body weight Symptoms: Reduced foetal weight, foetal mortality Result: No effects on fertility, Some evidence of adverse ef-

fects on development, based on animal experiments.

Test Type: Three-generation reproduction toxicity study

Species: Rat

Application Route: Oral

General Toxicity F1: LOAEL: 0.8 mg/kg body weight

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fluralaner / Moxidectin / Pyrantel Pamoate Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5.1 28.09.2024 7950971-00012 Date of first issue: 17.03.2021

Symptoms: Reduced foetal weight, foetal mortality

Result: No effects on fertility, Some evidence of adverse effects on development, based on animal experiments.

Effects on foetal develop-

ment

Test Type: Embryo-foetal development

Species: Rat

Application Route: Oral

General Toxicity Maternal: LOAEL: 10 mg/kg body weight Embryo-foetal toxicity: LOAEL: 10 mg/kg body weight

Result: Skeletal malformations

Remarks: The effects were seen only at maternally toxic dos-

es.

Test Type: Embryo-foetal development

Species: Rabbit Application Route: Oral

General Toxicity Maternal: LOAEL: 5 mg/kg body weight Developmental Toxicity: NOAEL: 10 mg/kg body weight Result: No teratogenic effects, No embryotoxic effects

Reproductive toxicity - As-

sessment

Some evidence of adverse effects on development, based on

animal experiments.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

Not classified based on available information.

Components:

2,6-Di-tert-butyl-p-cresol:

Assessment : No significant health effects observed in animals at concentra-

tions of 100 mg/kg bw or less.

Moxidectin:

Target Organs : Central nervous system

Assessment : Causes damage to organs through prolonged or repeated

exposure.

Repeated dose toxicity

Components:

4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Species : Dog
NOAEL : 10 mg/kg
LOAEL : 30 mg/kg
Application Route : Ingestion
Exposure time : 3 d

19 / 31

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fluralaner / Moxidectin / Pyrantel Pamoate Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5.1 28.09.2024 7950971-00012 Date of first issue: 17.03.2021

Remarks : No significant adverse effects were reported

Species : Dog NOAEL : 600 mg/kg Application Route : Oral Exposure time : 19 d

Remarks : No significant adverse effects were reported

Species : Dog NOAEL : 600 mg/kg Application Route : Oral Exposure time : 30 d

Remarks : No significant adverse effects were reported

Species : Dog
NOAEL : 600 mg/kg
Application Route : Oral
Exposure time : 90 d

Remarks : No significant adverse effects were reported

Fluralaner:

Species : Dog
NOAEL : 1 mg/kg
Application Route : Oral
Exposure time : 52 Weeks
Target Organs : Liver

Remarks : No significant adverse effects were reported

Species : Juvenile dog LOAEL : 56 - 280 mg/kg

Application Route : Oral
Exposure time : 24 Weeks
Symptoms : Diarrhoea

Species : Rat
LOAEL : 400 mg/kg
Application Route : Oral
Exposure time : 90 Days

Target Organs : Liver, thymus gland

Species : Rat
NOAEL : 500 mg/kg
Application Route : Dermal
Exposure time : 90 Days
Target Organs : Liver

Remarks : No significant adverse effects were reported

Sodium n-dodecyl sulfate:

Species : Rat NOAEL : 488 mg/kg

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fluralaner / Moxidectin / Pyrantel Pamoate Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 7950971-00012
 Date of first issue: 17.03.2021

Application Route : Ingestion Exposure time : 90 Days

Remarks : Based on data from similar materials

2,6-Di-tert-butyl-p-cresol:

Species : Rat
NOAEL : 25 mg/kg
Application Route : Ingestion
Exposure time : 22 Months

Moxidectin:

Species : Mouse
NOAEL : 3.9 mg/kg
LOAEL : 15.4 mg/kg
Application Route : Oral
Exposure time : 4 Weeks
Symptoms : Tremors

Species : Rat
NOAEL : 3.9 mg/kg
LOAEL : 7.9 mg/kg
Application Route : Oral
Exposure time : 13 Weeks

Target Organs : Central nervous system Symptoms : Tremors, Salivation

Species : Dog
NOAEL : 0.3 mg/kg
LOAEL : 0.9 mg/kg
Application Route : Oral
Exposure time : 90 Days

Target Organs : Central nervous system

Symptoms : Tremors, Lachrymation, Salivation

Species : Dog NOAEL : 1.15 mg/kg Application Route : Oral Exposure time : 52 Weeks

Target Organs : Central nervous system Symptoms : Tremors, Lachrymation

Aspiration toxicity

Not classified based on available information.

Components:

Fluralaner: Not applicable

21/31

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fluralaner / Moxidectin / Pyrantel Pamoate Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5.1 28.09.2024 7950971-00012 Date of first issue: 17.03.2021

11.2 Information on other hazards

Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

Experience with human exposure

Components:

4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Ingestion : Symptoms: Abdominal pain, Nausea, Vomiting, Diarrhoea,

Headache, Dizziness, Fever

Fluralaner:

Skin contact : Remarks: May irritate skin.

Eye contact : Remarks: May cause eye irritation.

Moxidectin:

Inhalation : Remarks: No human information is available. Skin contact : Remarks: No human information is available. Eye contact : Remarks: No human information is available. Ingestion : Remarks: No human information is available.

SECTION 12: Ecological information

12.1 Toxicity

Components:

4,4'-methylenebis[3-hydroxy-2-naphthoic] acid, compound with (E)-1,4,5,6-tetrahydro-1-methyl-2-[2-(2-thienyl)vinyl]pyrimidine (1:1):

Ecotoxicology Assessment

Acute aquatic toxicity : Toxic effects cannot be excluded

Chronic aquatic toxicity : Toxic effects cannot be excluded

Fluralaner:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 0.0488 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other : EC50 (Daphnia magna (Water flea)): > 0.015 mg/l

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fluralaner / Moxidectin / Pyrantel Pamoate **Formulation**

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 Date of first issue: 17.03.2021 7950971-00012 5.1 28.09.2024

Exposure time: 48 h aquatic invertebrates

Method: OECD Test Guideline 202

Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic

plants

NOEC (Pseudokirchneriella subcapitata (green algae)): >= 0.08 ma/l

Exposure time: 72 h

Method: OECD Test Guideline 201

Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic tox-

icity)

NOEC: >= 0.049 mg/lExposure time: 21 d

Species: Zebrafish

Method: OECD Test Guideline 204

Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other : aquatic invertebrates (Chron-

ic toxicity)

NOEC: 0.0736 µg/l Exposure time: 21 d

Species: Daphnia magna (Water flea) Method: OECD Test Guideline 211

M-Factor (Chronic aquatic

toxicity)

1,000

Sodium n-dodecyl sulfate:

Toxicity to fish LC50 (Pimephales promelas (fathead minnow)): 29 mg/l

Exposure time: 96 h

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Ceriodaphnia dubia (water flea)): 5.55 mg/l

Exposure time: 48 h

Toxicity to algae/aguatic

plants

ErC50 (Desmodesmus subspicatus (green algae)): > 120 mg/l

Exposure time: 72 h

NOEC (Desmodesmus subspicatus (green algae)): 30 mg/l

Exposure time: 72 h

EC50: 135 mg/l Toxicity to microorganisms

Exposure time: 3 h

Toxicity to fish (Chronic tox-

icity)

NOEC: >= 1.357 mg/lExposure time: 42 d

Species: Pimephales promelas (fathead minnow)

Toxicity to daphnia and other aquatic invertebrates (Chron-

NOEC: 0.88 mg/l Exposure time: 7 d

ic toxicity)

Species: Ceriodaphnia dubia (water flea)

2,6-Di-tert-butyl-p-cresol:

Toxicity to fish LC50 (Danio rerio (zebra fish)): > 0.57 mg/l

Exposure time: 96 h

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fluralaner / Moxidectin / Pyrantel Pamoate Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5.1 28.09.2024 7950971-00012 Date of first issue: 17.03.2021

Method: Directive 67/548/EEC, Annex V, C.1.

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 0.48 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

ErC50 (Pseudokirchneriella subcapitata (green algae)): > 0.24

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 0.24

mg/l

Exposure time: 72 h

Method: OECD Test Guideline 201

M-Factor (Acute aquatic tox-

icity)

1

Toxicity to microorganisms : EC50 : > 10,000 mg/l

Exposure time: 3 h

Method: OECD Test Guideline 209

Toxicity to fish (Chronic tox-

icity)

NOEC: 0.053 mg/l

Exposure time: 30 d

Species: Oryzias latipes (Japanese medaka)

Method: OECD Test Guideline 210

Toxicity to daphnia and other :

aquatic invertebrates (Chron-

ic toxicity)

NOEC: 0.316 mg/l Exposure time: 21 d

Species: Daphnia magna (Water flea)

M-Factor (Chronic aquatic

toxicity)

: 1

Moxidectin:

Toxicity to fish : LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.0006 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

LC50 (Oncorhynchus mykiss (rainbow trout)): 0.0002 mg/l

Exposure time: 96 h

Method: OECD Test Guideline 203

Toxicity to daphnia and other :

aquatic invertebrates

EC50 (Daphnia magna (Water flea)): 0.00003 mg/l

Exposure time: 48 h

Method: OECD Test Guideline 202

Toxicity to algae/aquatic

plants

EC50 (Pseudokirchneriella subcapitata (green algae)): 0.087

ma/l

Exposure time: 72 h

Method: OECD Test Guideline 201

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fluralaner / Moxidectin / Pyrantel Pamoate Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 7950971-00012
 Date of first issue: 17.03.2021

M-Factor (Acute aquatic tox-

icity)

10,000

M-Factor (Chronic aquatic

toxicity)

10,000

12.2 Persistence and degradability

Components:

Sodium n-dodecyl sulfate:

Biodegradability : Result: Readily biodegradable.

Biodegradation: 95 % Exposure time: 28 d

Method: OECD Test Guideline 301B

2,6-Di-tert-butyl-p-cresol:

Biodegradability : Result: Not readily biodegradable.

Biodegradation: 4.5 % Exposure time: 28 d

Method: OECD Test Guideline 301C

12.3 Bioaccumulative potential

Components:

Fluralaner:

Bioaccumulation : Species: Zebrafish

Bioconcentration factor (BCF): 79.4 Method: OECD Test Guideline 305

Partition coefficient: n-

octanol/water

log Pow: 4.5

Sodium n-dodecyl sulfate:

Partition coefficient: n-

octanol/water

log Pow: 0.83

2,6-Di-tert-butyl-p-cresol:

Bioaccumulation : Species: Cyprinus carpio (Carp)

Bioconcentration factor (BCF): 330 - 1,800

Partition coefficient: n-

octanol/water

: log Pow: 5.1

Moxidectin:

Partition coefficient: n-

octanol/water

: log Pow: 4.7

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fluralaner / Moxidectin / Pyrantel Pamoate Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5.1 28.09.2024 7950971-00012 Date of first issue: 17.03.2021

12.4 Mobility in soil

Components:

Fluralaner:

Distribution among environ-

mental compartments

: log Koc: 4.1

12.5 Results of PBT and vPvB assessment

Product:

Assessment : This substance/mixture contains no components considered

to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of

0.1% or higher.

Components:

Fluralaner:

Assessment : Substance is not persistent, bioaccumulative, and toxic (PBT).

12.6 Endocrine disrupting properties

Product:

Assessment : The substance/mixture does not contain components consid-

ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at

levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations.

According to the European Waste Catalogue, Waste Codes

are not product specific, but application specific.

Waste codes should be assigned by the user, preferably in

discussion with the waste disposal authorities.

Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste han-

dling site for recycling or disposal.

If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fluralaner / Moxidectin / Pyrantel Pamoate Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5.1 28.09.2024 7950971-00012 Date of first issue: 17.03.2021

ADN : UN 3077
ADR : UN 3077
RID : UN 3077
IMDG : UN 3077
IATA : UN 3077

14.2 UN proper shipping name

ADN : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(Fluralaner, Moxidectin)

ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(Fluralaner, Moxidectin)

RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(Fluralaner, Moxidectin)

IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID,

N.O.S.

(Fluralaner, Moxidectin)

IATA : Environmentally hazardous substance, solid, n.o.s.

(Fluralaner, Moxidectin)

14.3 Transport hazard class(es)

Class Subsidiary risks

 ADN
 : 9

 ADR
 : 9

 RID
 : 9

 IMDG
 : 9

 IATA
 : 9

14.4 Packing group

ADN

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

ADR

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

RID

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fluralaner / Moxidectin / Pyrantel Pamoate Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5.1 28.09.2024 7950971-00012 Date of first issue: 17.03.2021

Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

IMDG

Packing group : III Labels : 9

EmS Code : F-A, S-F

IATA (Cargo)

Packing instruction (cargo : 956

aircraft)

Packing instruction (LQ) : Y956
Packing group : III

Labels : Miscellaneous

IATA (Passenger)

Packing instruction (passen: 956

ger aircraft)

Packing instruction (LQ) : Y956 Packing group : III

Labels : Miscellaneous

14.5 Environmental hazards

ADN

Environmentally hazardous : yes

ADR

Environmentally hazardous : yes

rid

Environmentally hazardous : yes

IMDG

Marine pollutant : yes

IATA (Passenger)

Environmentally hazardous : yes

IATA (Cargo)

Environmentally hazardous : yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fluralaner / Moxidectin / Pyrantel Pamoate Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5.1 28.09.2024 7950971-00012 Date of first issue: 17.03.2021

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) Conditions of restriction for the following entries should be considered: Number on list 75: If you intend to use this product as tattoo ink, please contact your vendor.

Substance(s) or mixture(s) are listed here according to their appearance in the regulation, irrespective of their use/purpose or the conditions of the restriction. Please refer to the conditions in corresponding Regulation to determine whether an entry is applicable to the placing on the market or

Quantity 2

200 t

not. Not applicable

Not applicable

Not applicable

Not applicable

REACH - Candidate List of Substances of Very High

Concern for Authorisation (Article 59).

Regulation (EC) on substances that deplete the ozone

layer

Regulation (EU) 2019/1021 on persistent organic pollu-

tants (recast)

Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import

of dangerous chemicals

REACH - List of substances subject to authorisation : Not applicable

(Annex XIV)

E1

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of

major-accident hazards involving dangerous substances.

Quantity 1
ENVIRONMENTAL 100 t

HAZARDS

Other regulations:

Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fluralaner / Moxidectin / Pyrantel Pamoate Formulation

Version Revision Date: SDS Number: Date of last issue: 06.07.2024 5.1 28.09.2024 7950971-00012 Date of first issue: 17.03.2021

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information : Items where changes have been made to the previous version

are highlighted in the body of this document by two vertical

lines.

Full text of H-Statements

H301 : Toxic if swallowed. H302 : Harmful if swallowed. H315 : Causes skin irritation.

H318 : Causes serious eye damage. H319 : Causes serious eye irritation.

H332 : Harmful if inhaled.

H361d : Suspected of damaging the unborn child.

H372 : Causes damage to organs through prolonged or repeated

exposure.

H400 : Very toxic to aquatic life.

H410 : Very toxic to aquatic life with long lasting effects.H412 : Harmful to aquatic life with long lasting effects.

Full text of other abbreviations

Acute Tox. : Acute toxicity

Aquatic Acute : Short-term (acute) aquatic hazard Aquatic Chronic : Long-term (chronic) aquatic hazard

Eye Dam. : Serious eye damage

Eye Irrit. : Eye irritation

Repr. : Reproductive toxicity

Skin Irrit. : Skin irritation

STOT RE : Specific target organ toxicity - repeated exposure

IE OEL : Ireland. List of Chemical Agents and Carcinogens with Occu-

pational Exposure Limit Values - Code of Practice, Schedule 1

and 2

IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



Fluralaner / Moxidectin / Pyrantel Pamoate Formulation

 Version
 Revision Date:
 SDS Number:
 Date of last issue: 06.07.2024

 5.1
 28.09.2024
 7950971-00012
 Date of first issue: 17.03.2021

tional Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

Further information

Sources of key data used to compile the Safety Data Sheet

Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agen-

cy, http://echa.europa.eu/

Classification of the mixture: Classification procedure:

Repr. 2 H361d Calculation method
Aquatic Acute 1 H400 Calculation method
Aquatic Chronic 1 H410 Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN